Korea Customs Service detected 4,155 illegal imports of obesity treatments including Wegovy and Mounjaro in the first half of 2026, 3.5 times the total for all of 2025. Postal shipments account for 84.8 percent of all cases since 2024. The surge raises questions about quality, counterfeits, and…
On Aug. 24, 2026, the Korea Customs Service announced that it had detected 4,155 illegal import cases involving obesity treatments including Wegovy and Mounjaro in the first half of 2026. The figure is 3.5 times the 1,189 cases detected in all of 2025, and it follows a 2024 in which the total was exactly four. Cumulatively, the agency has detected 5,348 cases from 2024 through June 2026. The totals measure detected activity, not total inflow, and the agency has not defined what constitutes a case.
The announcement, released at 1:15 p.m., is the clearest public measure to date of how quickly demand for the two peptide-based obesity drugs has spilled into unregulated import channels since their commercial arrival in Korea. Novo Nordisk, the maker of Wegovy, held the drug's launch event at a hotel in Seoul on Oct. 15, 2024. The enforcement record begins almost exactly at that point.
A Korea Customs Service official framed the enforcement stance in direct terms. "Bringing Wegovy and Mounjaro into the country without authorization is a serious illegal act that may be punishable under the Customs Act," the official said. Both drugs are designated harmful drugs under Korean law, a classification that gives customs the authority to intercept them at the border.
Year by year, the channel breakdown is stark:
Direct overseas purchases sent through international mail dominate every period. Postal shipments account for 84.8 percent of all cases detected from 2024 through June 2026, and the share is stable whether each year is taken alone: 88.0 percent of 2025 cases and 84.0 percent of H1 2026 cases. The postal channel scaled up from two detected cases in 2024 to 1,046 in 2025 to 3,489 in a single half-year.
The traveler-carried channel is the one that changed shape. After one detected case in 2024 and 134 in all of 2025, customs logged 656 cases in the first half of 2026 alone, raising the traveler share from about 11 percent of 2025 cases to about 16 percent of the H1 2026 total. Whether that reflects more travelers carrying drugs for personal use, couriers moving product on passenger routes, or new screening attention at airports is not disclosed. Express shipments remain a minor route, moving from 1 to 9 to 10.
The 3.5-times comparison warrants a careful read. It pits six months of 2026 against the full year of 2025, not like-for-like periods. If the second half of 2026 resembles the first, the annual total would run well ahead of the stated ratio. The figures also measure customs enforcement activity, not the true volume of illegal imports; an unknown share of shipments is presumably never detected. What the data can establish is direction and composition, and both point the same way: rapid growth in personal, small-quantity importation of these drugs, overwhelmingly by post.
The legal framework is a designation by the Minister of Food and Drug Safety. Wegovy and Mounjaro are classified as harmful drugs, which prohibits their import in any quantity without a recommendation for exemption from import requirements verification . The prohibition covers all three entry channels captured in the data: postal, traveler-carried, and express.
The designation attaches to the product, not to a quantity. One seized multi-dose pen is as illegal as a carton of them, which is why the enforcement record is built from small parcels rather than commercial shipments. The exemption mechanism exists on paper: a recommendation for exemption from import requirements verification is the only lawful doorway for these drugs. The announcement gives no indication of the quantities, indications, or documentation that would make a personal import lawful. For a patient overseas who believes they have a legitimate need for a prescribed peptide medicine, the boundary between lawful and unlawful import is not visible in the enforcement notice.
The Korea Customs Service acts on that designation at the border under the Customs Act , detaining and destroying confiscated products. Nothing intercepted under the program is returned to the sender, diverted to legitimate patients, or released for personal use. A Korea Customs Service official made the operational posture explicit. "We will thoroughly block the illegal entry of harmful drugs at the border," the official said.
Destruction as the default outcome carries a scientific cost. The agency reports counts of cases, not the identity, purity, or origin of the contents, and it has not said whether any confiscated products were tested. Whether some were counterfeit, degraded, or of unknown manufacture is an open question. The agency says unauthorized importation may be punishable under the Customs Act, but it has not said whether prosecutions or penalties have been pursued in any of the 5,348 detected cases.
The underlying biology explains why these specific compounds generate this kind of illicit demand. Semaglutide https://peptideatlas.co/peptides/semaglutide is a GLP-1 receptor agonist. It amplifies glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on central pathways that reduce appetite and food intake. Tirzepatide https://peptideatlas.co/peptides/tirzepatide is a dual agonist of the GIP and GLP-1 receptors, combining the incretin effects of GLP-1 signaling with GIP receptor activation, and it has become a clinical reference point for weight-loss efficacy in the incretin class.
Both are once-weekly injectable peptides engineered from the incretin system , the set of gut hormones released after meals. Native GLP-1 and GIP are degraded within minutes by the enzyme DPP-4, so the marketed drugs are structural modifications: semaglutide is an acylated GLP-1 analog that binds albumin and resists enzymatic cleavage, and tirzepatide is a single engineered peptide that activates both receptors. The practical consequence is the same in both cases: stable, potent injectable molecules that must be manufactured under sterile conditions, formulated at exact doses, and delivered through a scheduled titration.
That chemistry is exactly what makes the informal market dangerous. Peptides are not small molecules that behave predictably once pressed into a tablet. They require synthesis or recombinant production, purification, sterile fill, and temperature control. A parcel sent through international mail breaks every link in that chain. The recipient cannot verify identity, strength, or sterility, and a multi-dose pen that has been frozen, heated, or mislabeled is a different product from the one the label claims.
Prescribed use starts at a low dose and escalates over weeks under monitoring; unsupervised use skips the titration and the monitoring. The 2026 case report describing starvation-type euglycemic ketoacidosis after unsupervised tirzepatide use in a non-obese, non-diabetic woman PMID 42381258 is a documented example of what can happen when a potent incretin peptide is self-administered by someone outside the approved profile, which is precisely the population the gray market serves.
The Peptide Atlas registry files 668 registered clinical trials for semaglutide and 251 for tirzepatide. The semaglutide file lists 10 trials currently recruiting, with a phase breakdown of 4 Phase 2, 4 Phase 4, and 1 Phase 3 trials. The tirzepatide file also lists 10 recruiting trials, with 5 Phase 2, 2 Phase 4, and 1 Phase 3 designations. Indexed PubMed literature stands at 197 papers for semaglutide and 188 for tirzepatide.
The recruiting trials show how far the two molecules have moved beyond obesity as a sole indication. Semaglutide is being studied in the LIFETRAIN trial NCT07586150 for personalized pharmaco-lifestyle interventions in severe mental illness, in a Phase 2 trial for Stage 1 type 1 diabetes NCT07430332 , in the SHIELD-T1D trial combining Shingrix with a GLP-1 agonist for beta-cell preservation in recent-onset type 1 diabetes NCT07614412 , in the SHAPE-ENDO trial of pre-surgical optimization in obesity with early-stage endometrial cancer NCT07462663 , in a Phase 4 trial of metabolic surgery for atrial fibrillation elimination NCT07027969 , and in a Phase 4 pediatric obesity program NCT06977438 . Tirzepatide is being studied for type 1 diabetes with overweight or obesity NCT06180616 , for cannabis use disorder NCT07468552 , for skeletal muscle morphology and physical function in overweight and sarcopenic adults NCT07609160 , for atrial fibrillation recurrence after catheter ablation in patients with obesity and heart failure with preserved ejection fraction NCT07630454 , and in combination with the agent NA-931 in adults who are overweight or obese NCT06732245 .
The indication spread is itself part of the demand story. GLP-1 receptor signaling is now understood to reach beyond glucose metabolism into cardiovascular, renal, and central nervous system function, which is why the same molecule is being tested for atrial fibrillation, endometrial cancer, pediatric obesity, and beta-cell preservation in type 1 diabetes, and why the dual agonist is being tested for cannabis use disorder, sarcopenia, and heart failure with preserved ejection fraction. The trial NCT07027969, a Phase 4 study of metabolic surgery for atrial fibrillation elimination, appears in both the semaglutide and tirzepatide files, a reminder that the two molecules are often evaluated in overlapping patient populations.
Recent indexed literature tracks the same widening. For semaglutide, 2026 papers cover long-term renal outcomes in non-diabetic obesity with chronic kidney disease or hypertension PMID 42340790 , weight-lowering drugs and natural female fertility PMID 42307450 , effort-based decision-making in major depressive disorder PMID 42054055 , the STRIDE trial in peripheral artery disease and diabetes PMID 41780559 , and retinal vascular events PMID 42348481 . For tirzepatide, recent work includes a real-world comparison with SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease PMID 42397506 , the starvation-type ketoacidosis case report PMID 42381258 , a review of molecular mechanisms and clinical translation PMID 42387035 , a retrospective cohort in type 1 diabetes PMID 42387290 , and a multicenter real-world comparison with semaglutide for obesity PMID 42383938 .
The scale of that evidence base is part of the story. Clinical legitimacy for these peptides is expanding at the same moment that illicit demand is expanding, and the two curves reinforce each other: broader indications generate more awareness, and more awareness generates more attempts to obtain the drugs without a prescription.
The enforcement record establishes a trend; it does not establish the safety or identity of what is arriving. Third-party laboratory purity tests on file at Peptide Atlas show 8 tests for semaglutide with a highest observed purity of 99.979 percent, and 4 tests for tirzepatide with a highest observed purity of 99.864 percent. Those figures describe tested samples. Products moving through illicit postal channels have no equivalent assurance, and the Korean data do not disclose whether any confiscated products were counterfeit or of unknown origin.
For clinicians, the practical implication is that patients may be using these drugs without disclosure. A patient who obtains semaglutide or…
Peptides referenced: Semaglutide, Tirzepatide, Glucagon, GLP-1.
Related reading: IndexBox Lists US$4,000 UK Peptide Serum Report, No Findings, Weekly GLP-1 Drug Beats Daily Insulin in Thalassaemia-Linked Diabetes, Energean shares slide 12.3% in 2026 while Brent holds above $92, Oral Wegovy Outruns Foundayo in the First Full Quarter of Oral Competition.